Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit [Yahoo! Finan...
Serina Therapeutics, Inc. (SER)
Company Research
Source: Yahoo! Finance
its proprietary POZ Platform TM drug delivery technology, today announced that Randall Moreadith, MD, Ph.D., Chief Development Officer, will present at the 4th Annual mRNA-Based Therapeutics Summit. The conference will take place from July 29-31, 2024, in Boston, MA. Dr. Moreadith's presentation, titled "Overcoming Anti-PEG Antibody Responses to Increase Potency & Decrease Adverse Side Effects of mRNA-LNP Formulations”, is scheduled for 9:00 AM ET on Monday, July 29. In this talk, Dr. Moreadith will present novel data on Serina Therapeutics' innovative POZ-lipid, a proprietary technology that aims to significantly advance the safety and efficacy of mRNA-LNP formulations. These data show that POZ-lipid does not induce an IgM or IgG antibody response, even with repeated dosing in in vivo models. This finding is crucial because the PEG-lipids currently used in mRNA vaccines can elicit an anti-PEG antibody response. This response is associated with serious adverse events, including an
Show less
Read more
Impact Snapshot
Event Time:
SER
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SER alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SER alerts
High impacting Serina Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SER
News
- Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]Yahoo! Finance
- Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business HighlightsGlobeNewswire
- Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics SummitGlobeNewswire
- Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation [Yahoo! Finance]Yahoo! Finance
SER
Sec Filings
- 9/24/24 - Form 4
- 9/20/24 - Form 4
- 9/16/24 - Form 4
- SER's page on the SEC website